Good manufacturing practice (GMP) certificates from the Danish Medicines Agency (DKMA) are accepted by all European Union (EU) health authorities. Gaining certification allows Cambrex to accelerate rollout of products in the EU and offer finished dosage forms to clients.
“This commercially important and significant milestone for Cambrex confirms our commitment to quality in every aspect of operations management and reflects our efforts to sustain and continuously improve quality platforms”, said Ashok Narasimhan, President of Cambrex Zenara.
Cambrex acquired 51 per cent of Zenara in November and intends to buy the remaining 51 per cent in 2016.